NCT03943901View on ClinicalTrials.gov

Split-Dose R-CHOP for Older Adults With DLBCL

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 17, 2021

Primary Completion Date

January 13, 2025

Study Completion Date

February 28, 2027

Conditions
Diffuse Large B Cell LymphomaDLBCLCancer
Interventions
DRUG

Rituximab

Rituximab is a monoclonal antibody

DRUG

Cyclophosphamide

Chemotherapy drug, alkylating agent

DRUG

Doxorubicin

Chemotherapy drug, anthracycline antibiotic

DRUG

Vincristine

Chemotherapy drug, plant alkaloid

DRUG

Prednisone

Steroid, anti-inflammatory

BIOLOGICAL

Pegfilgrastim

Granulocyte stimulating factor, biologic response modifier

Trial Locations (1)

53705

University of Wisconsin Carbone Cancer Center, Madison

All Listed Sponsors
collaborator

Medical College of Wisconsin

OTHER

lead

University of Wisconsin, Madison

OTHER